

Virginia V Ferretti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7243524/publications.pdf>

Version: 2024-02-01

99
papers

5,632
citations

172207

29
h-index

76769

74
g-index

101
all docs

101
docs citations

101
times ranked

7431
citing authors

#	ARTICLE	IF	CITATIONS
1	Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. <i>New England Journal of Medicine</i> , 2013, 369, 2379-2390.	13.9	1,698
2	JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. <i>Blood</i> , 2014, 123, 1544-1551.	0.6	507
3	Clinical significance of somatic mutation in unexplained blood cytopenia. <i>Blood</i> , 2017, 129, 3371-3378.	0.6	379
4	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. <i>Blood</i> , 2014, 124, 1062-1069.	0.6	340
5	Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. <i>Leukemia</i> , 2016, 30, 431-438.	3.3	216
6	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	0.8	204
7	Ambient Air Pollution and Adult Asthma Incidence in Six European Cohorts (ESCAPE). <i>Environmental Health Perspectives</i> , 2015, 123, 613-621.	2.8	197
8	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , 2016, 128, 2527-2532.	0.6	149
9	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014, 25, 1404-1410.	0.6	133
10	Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. <i>Leukemia</i> , 2015, 29, 66-75.	3.3	122
11	Nonexpanded Mesenchymal Stem Cells for Regenerative Medicine: Yield in Stromal Vascular Fraction from Adipose Tissues. <i>Tissue Engineering - Part C: Methods</i> , 2010, 16, 1515-1521.	1.1	99
12	Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2017, 102, 2077-2085.	1.7	90
13	Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. <i>Blood</i> , 2013, 121, 4388-4395.	0.6	83
14	The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. <i>Haematologica</i> , 2015, 100, 246-252.	1.7	73
15	Is drop-out from obesity treatment a predictable and preventable event?. <i>Nutrition Journal</i> , 2014, 13, 13.	1.5	70
16	Epidemiology of multiple sclerosis in south-western Sardinia. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1282-1289.	1.4	66
17	CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. <i>Blood</i> , 2014, 123, 2416-2419.	0.6	66
18	Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. <i>Leukemia</i> , 2019, 33, 2495-2505.	3.3	61

#	ARTICLE	IF	CITATIONS
19	Relationship between clone metrics and clinical outcome in clonal cytopenia. <i>Blood</i> , 2021, 138, 965-976.	0.6	58
20	Cross-sectional associations between air pollution and chronic bronchitis: an ESCAPE meta-analysis across five cohorts. <i>Thorax</i> , 2014, 69, 1005-1014.	2.7	56
21	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2014, 99, 489-496.	1.7	55
22	Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. <i>American Journal of Hematology</i> , 2010, 85, 46-50.	2.0	52
23	Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. <i>Oncologist</i> , 2019, 24, e720-e729.	1.9	52
24	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , 2017, 31, 2449-2457.	3.3	51
25	Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project. <i>Blood</i> , 2014, 124, 405-405.	0.6	47
26	Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. <i>Oncotarget</i> , 2017, 8, 101735-101744.	0.8	45
27	Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the Invece.Ab population-based study. <i>BMC Geriatrics</i> , 2013, 13, 98.	1.1	39
28	Validation of follicular lymphoma international prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. <i>British Journal of Haematology</i> , 2010, 149, 455-457.	1.2	36
29	The possible role of burden of therapy on the risk of myeloma extramedullary spread. <i>Annals of Hematology</i> , 2017, 96, 73-80.	0.8	34
30	Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. <i>European Journal of Haematology</i> , 2010, 85, 405-415.	1.1	30
31	Impact of mutational status on pregnancy outcome in patients with essential thrombocythemia. <i>Haematologica</i> , 2015, 100, e443-e445.	1.7	30
32	Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Leukemia</i> , 2020, 34, 1462-1466.	3.3	30
33	Circulating endothelial cells in COVID-19. <i>American Journal of Hematology</i> , 2020, 95, E187-E188.	2.0	28
34	Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2019, 94, E185-E188.	2.0	26
35	Influence of socio-demographic features and apolipoprotein E epsilon 4 expression on the prevalence of dementia and cognitive impairment in a population of 70-74-year olds: The InveCe.Ab study. <i>Archives of Gerontology and Geriatrics</i> , 2015, 60, 334-343.	1.4	25
36	Monoclonal gammopathy of undetermined significance: a new proposal of workup. <i>European Journal of Haematology</i> , 2013, 91, 356-360.	1.1	24

#	ARTICLE	IF	CITATIONS
37	Epidemiology and Geographical Variation of Myasthenia Gravis in the Province of Pavia, Italy. <i>Neuroepidemiology</i> , 2012, 38, 100-105.	1.1	23
38	Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma. <i>Hematological Oncology</i> , 2017, 35, 296-302.	0.8	23
39	Psychological care of caregivers, nurses and physicians: a study of a new approach. <i>Cancer Medicine</i> , 2014, 3, 101-110.	1.3	20
40	Machine Learning-based Voice Assessment for the Detection of Positive and Recovered COVID-19 Patients. <i>Journal of Voice</i> , 2021, , .	0.6	20
41	High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO. <i>British Journal of Haematology</i> , 2018, 182, 807-815.	1.2	19
42	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. <i>American Journal of Hematology</i> , 2019, 94, 1193-1199.	2.0	18
43	Human Cytomegalovirus-Specific T-Cell Reconstitution and Late-Onset Cytomegalovirus Infection in Hematopoietic Stem Cell Transplantation Recipients following Letermovir Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 211.e1-211.e9.	0.6	18
44	Neurological Complications Involving the Central Nervous System After Allogeneic Hematopoietic Stem Cell Transplantation During a Period of Evolution in Transplant Modalities: A Cohort Analysis. <i>Transplantation</i> , 2017, 101, 616-623.	0.5	17
45	Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. <i>Hematological Oncology</i> , 2019, 37, 160-167.	0.8	15
46	A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders. <i>British Journal of Haematology</i> , 2019, 187, 441-446.	1.2	13
47	Nutritional parameters associated with prognosis in non-critically ill hospitalized COVID-19 patients: The NUTRI-COVID19 study. <i>Clinical Nutrition</i> , 2022, 41, 2980-2987.	2.3	13
48	Long Term Evaluation of the Impact of Autologous Peripheral Blood Stem Cell Transplantation in Multiple Myeloma: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2013, 8, e75047.	1.1	11
49	Clinical, virological and immunological evolution of the olfactory and gustatory dysfunction in COVID-19. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2022, 43, 103170.	0.6	11
50	Facing erythrocytosis: Results of an international physician survey. <i>American Journal of Hematology</i> , 2019, 94, E225-E227.	2.0	10
51	Autologous stem cell transplantation with <i>in vivo</i> purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. <i>American Journal of Hematology</i> , 2015, 90, 230-234.	2.0	9
52	Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies. <i>British Journal of Haematology</i> , 2015, 168, 301-302.	1.2	9
53	The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. <i>Future Oncology</i> , 2018, 14, 2713-2723.	1.1	9
54	Men with COVID-19 die. Women survive. <i>Maturitas</i> , 2022, 158, 34-36.	1.0	9

#	ARTICLE	IF	CITATIONS
55	Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis. <i>Hematological Oncology</i> , 2020, 38, 689-697.	0.8	7
56	Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. <i>American Journal of Hematology</i> , 2020, 95, 1473-1478.	2.0	7
57	Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders. <i>American Journal of Hematology</i> , 2021, 96, E210-E214.	2.0	7
58	Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms. <i>Oncotarget</i> , 2017, 8, 33416-33421.	0.8	7
59	Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: results from a large cohort of patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 386-393.	1.4	6
60	Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice. <i>Leukemia and Lymphoma</i> , 2019, 60, 2968-2974.	0.6	5
61	Early T cell reconstitution and cytokine profile may help to guide a personalized management of human cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2021, 135, 104734.	1.6	5
62	Anti-Lymphoma Activity of Interferon-Free Antiviral Treatment in Patients with Indolent B-Cell Lymphomas Associated with Hepatitis C Virus Infection. <i>Blood</i> , 2015, 126, 3938-3938.	0.6	5
63	Impaired virus-specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib. <i>Hematological Oncology</i> , 2020, 38, 554-559.	0.8	4
64	Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis. <i>Hematological Oncology</i> , 2021, 39, 589-592.	0.8	4
65	Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 1901-1902.	0.6	3
66	SRSF2 Mutations Identify a Distinct Subtype of Myeloid Neoplasm Across Myelodysplastic Syndromes and Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 4337-4337.	0.6	3
67	Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms. <i>Blood</i> , 2022, 139, 2716-2720.	0.6	3
68	Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates. <i>Leukemia and Lymphoma</i> , 2014, 55, 1397-1398.	0.6	2
69	Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: an in vivo confocal study. <i>Leukemia and Lymphoma</i> , 2015, 56, 3440-3441.	0.6	2
70	Real-life study of imatinib therapy in chronic phase-chronic myeloid leukemia: A novel retrospective observational longitudinal analysis. <i>Hematology</i> , 2017, 22, 1-8.	0.7	2
71	The advantages of switch to subcutaneous bortezomib in the real life. <i>Leukemia and Lymphoma</i> , 2018, 59, 1505-1507.	0.6	2
72	Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network. <i>Annals of Hematology</i> , 2018, 97, 2107-2115.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Predictive Value of Mutation Analysis in the Diagnostic Approach to Patients with Unexplained Cytopenia. <i>Blood</i> , 2016, 128, 298-298.	0.6	2
74	High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study. <i>Blood</i> , 2014, 124, 2526-2526.	0.6	2
75	Targeted Next Generation Sequencing Identifies Novel Genetic Mutations in Patients with Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma or IgM-Monoclonal Gammopathies of Undetermined Significance. <i>Blood</i> , 2016, 128, 2928-2928.	0.6	2
76	Leptin Levels of the Perinatal Period Shape Offspring's Weight Trajectories through the First Year of Age. <i>Nutrients</i> , 2022, 14, 1451.	1.7	2
77	Evaluation of Virus-Specific T Cell Responses in Patients Affected with Myeloproliferative Neoplasms Treated with Ruxolitinib. <i>Blood</i> , 2019, 134, 1660-1660.	0.6	1
78	High Prevalence Of Extramedullary Relapse In Patients With Multiple Myeloma Treated With Novel Biological Agents. <i>Blood</i> , 2013, 122, 1896-1896.	0.6	1
79	Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin. <i>Blood</i> , 2014, 124, 3215-3215.	0.6	1
80	Somatic Mutations Are Frequently Detected in Chronic Myeloid Leukemia in Chronic Phase and Do Not Affect Response to Tyrosine-Kinase Inhibitors. <i>Blood</i> , 2016, 128, 1117-1117.	0.6	1
81	Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The "Rete Ematologica Lombarda/Hematology Network Of Lombardia Region". <i>Blood</i> , 2013, 122, 3003-3003.	0.6	1
82	JAK2 (V617F)-Positive Essential Thrombocythemia and Polycythemia Vera Are Different Expressions Of a Genotypic/Phenotypic Continuum. <i>Blood</i> , 2013, 122, 1592-1592.	0.6	1
83	Common Variation at 6q25.3 (TULP4) Influences Risk for Arterial Thrombosis in Myeloproliferative Neoplasms. <i>Blood</i> , 2015, 126, 4088-4088.	0.6	1
84	VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials. <i>Blood</i> , 2016, 128, 5711-5711.	0.6	1
85	Whole Body Diffusion Weighted MRI (WB DWI) for the Management of Multiple Myeloma: High Concordance between MRI Diffuse Pattern and BONE Marrow Plasma CELL Infiltration RATE. <i>Blood</i> , 2019, 134, 5495-5495.	0.6	1
86	INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION. <i>Hematological Oncology</i> , 2017, 35, 145-146.	0.8	0
87	DIRECT-ACTING ANTIVIRALS DURING OR AFTER IMMUNO-CHEMOTHERAPY IN HEPATITIS C VIRUS-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS. <i>Hematological Oncology</i> , 2017, 35, 194-196.	0.8	0
88	An mHealth app counseling patients and general practitioners about Multiple Myeloma. , 2017, , .		0
89	Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting. <i>Leukemia and Lymphoma</i> , 2021, 62, 3311-3312.	0.6	0
90	Prognostic impact of somatic mutations on time to first treatment: Results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E404-E408.	2.0	0

#	ARTICLE	IF	CITATIONS
91	Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.. Blood, 2009, 114, 760-760.	0.6	0
92	Confocal Microscopy Is Useful for Detection of Bortezomib Related Neuropathy (BOR-PN) in Multiple Myeloma (MM) Patients (PTS). Blood, 2014, 124, 5691-5691.	0.6	0
93	Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups. Blood, 2015, 126, 3740-3740.	0.6	0
94	Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials. Blood, 2015, 126, 5084-5084.	0.6	0
95	Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Administration. Blood, 2016, 128, 5695-5695.	0.6	0
96	ICA-EMA: A Tool for Assessing Nursing Complexity of Patients with Oncohematologic Disease in an Italian Center. Creative Nursing, 2019, 25, 157-168.	0.2	0
97	Waldenström Macroglobulinemia in Young Patients Treated in the Modern Era: A Multi-Institutional Italian Study. Blood, 2019, 134, 1539-1539.	0.6	0
98	Targeted Next Generation Sequencing Reveals Molecular Heterogeneity in Non-CLL Clonal B-Cell Lymphocytosis. Blood, 2019, 134, 1502-1502.	0.6	0
99	Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms. EJHaem, 0, , .	0.4	0